mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease

mAbxience United Kingdom England Germany Switzerland Italy Spain Latin America Argentina

View original content:https://www.prnewswire.co.uk/news-releases/mabxience-and-biosidus-sign-cdmo-agreement-for-the-manufacture-of-agalsidase-beta-for-the-treatment-of-fabry-disease-302051912.html